Point mutations and single amino acid substitutions in KRAS can cause its activation and affect cell proliferation, division, and apoptosis via the intracellular signaling cascade in about 40% of CRC patients [57–60]. The gene discussed is KRAS; the disease is colorectal carcinoma.